Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223 dichloride

- PMLiVE

Germany’s IQWiG delivers bad news for Bayer’s Eylea

Says drug provides no additional benefit over Novartis’ rival Lucentis in eye condition

Bayer symbol

Bayer puts research at heart of business growth

Says R&D-to-sales ratio will increase

- PMLiVE

Bayer photo contest to raise awareness of blood clot

Public invited to submit photos that take their breath away

- PMLiVE

AZ and Cancer Research UK to collaborate on new medicines

Charity’s scientists to be given access to pharma company’s molecule library

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

AZ seeks leg up in antiplatelet market with Brilinta antidote

Reversal agent has been developed by company's biotech subsidiary Medimmune

- PMLiVE

Eylea’s UK launch earns Bayer PMEA success

Receives the Cello Health Award for Launch Excellence

- PMLiVE

Nexium windfall lifts AZ in third quarter

Still to feel effects of generic competition

- PMLiVE

GSK first to file IL-5 antagonist for asthma

Mepolizumab submitted as a treatment for severe eosinophilic asthma

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

Bayer symbol

Bayer completes takeover of Chinese OTC company

Expands consumer health presence with Dihon purchase

Bayer symbol

Bayer CEO Dekkers points to ‘outstanding’ pharma growth

On target to meet company’s annual expectations of €7.5bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links